Introduction
============

Gastric cancer (GC) is the fourth most common type of malignancy worldwide, which results in 989,600 novel cases and 738,000 fatalities annually, specifically in Asian countries ([@b1-ol-07-05-1537]). Recent advancements in diagnosis and treatment modalities have been made, however, the prognosis of GC patients remains poor. As current therapeutic strategies are insufficient and do not achieve complete tumor ablation, it is important to analyze the molecular mechanisms of GC and identify novel biomarkers, as well as targets for therapeutic approaches, which may improve the clinical outcome for GC patients.

Collagen VI was initially identified as an extracellular matrix protein. It forms a microfilament network and binds to extracellular matrix proteins via its functional subdomains, which is important for the organization of fibrillar collagens and adhesion to the basement membrane ([@b2-ol-07-05-1537]). Collagen VI has recently attracted interest due to its involvement in breast and ovarian cancers ([@b3-ol-07-05-1537]--[@b5-ol-07-05-1537]). It is composed of three distinct α-chains (α1, -2 and -3) and collagen VI α3 (COL6A3) encodes the α3 chain, which is markedly longer than the other two chains ([@b6-ol-07-05-1537]). In a previous study, COL6A3 was shown to be upregulated in ovarian cancer ([@b7-ol-07-05-1537]), and Sherman-Baust *et al* ([@b5-ol-07-05-1537]) identified that the expression of COL6A3 was correlated with cisplatin resistance in ovarian cancer cell lines. Furthermore, highly or moderately differentiated ovarian tumors expressed lower levels of COL6A3 than poorly differentiated tumors, which indicated that the expression of COL6A3 was associated with the grade of the ovarian tumor ([@b5-ol-07-05-1537]). A recent exon array analysis study demonstrated that an alternative long isoform of COL6A3 was expressed, almost exclusively, in cancer samples, and may potentially serve as a novel cancer biomarker ([@b8-ol-07-05-1537]). Currently, the majority of studies relating to the oncogenic role of this gene focus on ovarian and breast cancer, however, the expression pattern and the biological functions of COL6A3 in human GC remain unknown.

In the present study, the authors investigated whether the expression level of COL6A3 was altered in GC, and a microarray meta-analysis was performed in order to assess the functional characteristics and molecular mechanisms of COL6A3 in GC.

Materials and methods
=====================

Gene expression patterns in GC
------------------------------

The Oncomine database (<http://www.oncomine.org>) was used to examine the differences in the transcriptional profiles between GC tissues and the adjacent normal tissues ([@b9-ol-07-05-1537]). Only the datasets that contained cancer versus normal analysis at the mRNA expression level were selected for analysis in the present study. In total, four GeneChip datasets, consisting of 318 paired GC and non-cancerous tissues, were selected according to the criteria shown in [Table I](#tI-ol-07-05-1537){ref-type="table"}.

Cell culture
------------

Five human GC cell lines (AGS, HGC-27, BGC-823, SGC-7901 and MGC80-3) and one immortalized gastric cell line (GES-1) were purchased from Shanghai Institute of Cell Biology (Shanghai, China). All cell lines were incubated in Dulbecco's modified Eagle's medium (Gibco-BRL, Carlsbad, CA, USA) with 10% fetal bovine serum (SAFC Biosciences Inc., Lenexa, KS, USA), 100 U/ml penicillin and 100 mg/ml streptomycin (Sigma-Aldrich, St. Louis, MO, USA).

Quantitative polymerase chain reaction (qPCR) analysis
------------------------------------------------------

TRIzol reagent (Invitrogen Life Technologies, Carlsbad, CA, USA) was used to extract the total RNA from whole cells, and reverse-transcription was conducted using a TaqMan^®^ Reverse Transcription kit (Applied Biosystems, Foster City, CA, USA). The DNA was amplified using an ABI^®^ 7500 Real-Time PCR system (Applied Biosystems) and SYBR Premix Ex Taq (Takara, Kusatsu, Japan). The ΔΔCt method was used to calculate the relative RNA expression, which was normalized to GAPDH expression. PCR was performed using the following primers: forward, 5′-GAGACGCAGTGAGTGGGAAA-3′ and reverse, 5′-AGAGTCTTGTGCTGCTTGCT-3′ for COL6A3; and forward, 5′-CTCTCTGCTCCTCCTGTTCGAC-3′ and reverse, 5′-TGAGCGATGTGGCTCGGCT-3′ for GAPDH.

Co-expression analysis
----------------------

The Oncomine database co-expression analysis tool was used to conduct the co-expression analysis of the microarray datasets. Using the co-expression score, the top 150 genes of each dataset were selected. The genes that appeared in at least two of the three datasets were defined as COL6A3 co-expressed genes.

Gene ontology (GO) and pathway enrichment analysis
--------------------------------------------------

GO and pathway enrichment analysis were conducted to examine COL6A3 co-expressed genes using the Database for Annotation, Visualization and Integrated Discovery (DAVID; <http://david.abcc.ncifcrf.gov/>). The categories, GOTERM_BP_3, GOTERM_CC_2 and GOTERM_MF_3 were selected, and the other options were set as defaults.

Construction of the gene interaction network
--------------------------------------------

The gene interaction network was constructed using a gene expression pattern scanner (GePS: <http://www.genomatix.de/>) as described previously ([@b10-ol-07-05-1537]).

Statistical analysis
--------------------

The independent Student's t test was used to analyze the differences between two groups. Statistical analysis was performed using SPSS software version 16.0 (SPSS, Chicago, IL, USA). Data are presented as the means ± SD. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

COL6A3 is commonly overexpressed in GC
--------------------------------------

To determine the changes in the transcriptional pattern of GC cells, microarray datasets from the studies by Chen *et al* ([@b11-ol-07-05-1537]), Cho *et al* ([@b12-ol-07-05-1537]), D'Errico *et al* ([@b13-ol-07-05-1537]) and Wang *et al* ([@b14-ol-07-05-1537]) were analyzed using the Oncomine database. COL6A3 demonstrated a significant overexpression in the GC cells (P=3.98×10^−15^; [Fig. 1A](#f1-ol-07-05-1537){ref-type="fig"}). To confirm this finding, the expression of COL6A3 in one immortalized gastric cell line (GES-1) and five GC cell lines (AGS, HGC-27, BGC-823, SGC-7901, MGC80-3) was analyzed using qPCR. The five GC cell lines exhibited ≥2.5-fold overexpression of COL6A3 compared with that of GES-1 cells ([Fig. 1B](#f1-ol-07-05-1537){ref-type="fig"}).

Genes co-expressed with COL6A3
------------------------------

A previous study indicated that genes which are co-expressed in different conditions may be functionally related or co-regulated ([@b15-ol-07-05-1537]). Therefore, a microarray co-expression analysis was conducted to identify the genes that were co-expressed with COL6A3. The dataset from the study by D'Errico *et al* ([@b13-ol-07-05-1537]) did not contain any co-expression data, therefore, the other three datasets consisting of 249 paired tissues were selected for inclusion in the co-expression analysis. Using a cut-off of the top 150 genes, which were identified by the co-expression score from each dataset, and with at least two appearances on the co-expressed list, 62 genes were identified as genes that were co-expressed with COL6A3 ([Table II](#tII-ol-07-05-1537){ref-type="table"}).

GO and pathway enrichment analysis of COL6A3 co-expressed genes
---------------------------------------------------------------

GO and pathway enrichment analysis were conducted using the DAVID functional annotation chart tool ([@b16-ol-07-05-1537]) to further analyze the underlying mechanisms of COL6A3 and its co-expressed genes. In total, 36 biological process, seven cellular constituents, seven molecular function terms and six Kyoto encyclopedia of genes and genomes pathways were indicated to be significantly enriched (P\<0.01; [Table III](#tIII-ol-07-05-1537){ref-type="table"}). The extracellular matrix organization indicated the most marked enrichment among the GO biological process terms. The predominant function of COL6A3 has been identified to be the organization of matrix components, which supported the reliability of the present analysis. Furthermore, cell processes, such as cell differentiation, cell-substrate adhesion, regulation of cell proliferation, regulation of cell migration, cell motion and cell migration, which are considered to be cancer-related biological processes, were enriched ([Fig. 2](#f2-ol-07-05-1537){ref-type="fig"}). This result indicated that COL6A3 may have been involved in the biological processes that promote the progression of GC.

Network analysis of COL6A3
--------------------------

A network analysis was conducted using Genomatix GePS to construct the functional connections of COL6A3 co-expressed genes. FN1 was highlighted in this network, as it functionally associated with 50 (81.9%) COL6A3 co-expressed genes, which indicated that FN1 may act as a significant regulator in the COL6A33 regulatory network ([Fig. 3](#f3-ol-07-05-1537){ref-type="fig"}).

Discussion
==========

COL6A3 is located on chromosome 2q37 and codes for the α-3 chain, one of the three α-chains of type VI collagen. It is hypothesized that COL6A3 accelerates cell anchoring and signaling through its interaction with integrin ([@b17-ol-07-05-1537]) and disruption of this gene results in muscular dystrophy ([@b2-ol-07-05-1537]). In addition to integrin, COL6A3 interacts with other matrix components, such as decorin, hyaluronan, heparan sulfate and NG2 proteoglycans ([@b18-ol-07-05-1537]). Furthermore, COL6A3 may promote neural crest cell migration and attachment, which is significant in the later stages of neural crest development ([@b19-ol-07-05-1537]).

Recently, COL6A3 has received increasing attention, due to its abnormal expression and the occurrence of alternative splicing in numerous types of cancer. Previous genome exon array studies have identified cancer-specific alternative splicing of exons 3, 4 and 6 of COL6A3 in colon, pancreatic, bladder and prostate cancer ([@b8-ol-07-05-1537],[@b20-ol-07-05-1537]). Furthermore, COL6A3 was identified to be overexpressed in pancreatic ([@b21-ol-07-05-1537]) and ovarian cancer ([@b7-ol-07-05-1537]), which was associated with the poor differentiation of tumor cells ([@b5-ol-07-05-1537]). Although COL6A3 has been investigated in numerous other types of cancer, its biological mechanisms and expression pattern in GC remain unclear.

In the era of post-genomic medicine, microarray meta-analysis has been demonstrated to be an effective strategy for identifying gene expression changes in various types of cancer ([@b22-ol-07-05-1537],[@b23-ol-07-05-1537]). In the present study, a microarray meta-analysis was performed to identify that COL6A3 was frequently overexpressed in hepatocellular carcinoma tissues, indicating that an increased expression of COL6A3 was associated with the carcinogenesis of GC. The underlying mechanisms that result in the increased expression of COL6A3 may relate to the transcriptional regulation of transforming growth factor (TGF)-β ([@b24-ol-07-05-1537]), however, this requires further investigation. To further define the biological mechanisms of COL6A3, a co-expression analysis was conducted to investigate the genes that are functionally related to, or co-regulated by, COL6A3. This identified 62 co-expression genes for COL6A3, the majority of which are involved in the processes of extracellular matrix organization such as lysyl oxidase, collagen type IV α2, TGF-β-induced and laminin γ1 ([Table II](#tII-ol-07-05-1537){ref-type="table"}). The functional network analysis of these co-expression genes was dominated by FN1, which demonstrated its predominant functional connections with other genes. FN1 is an adhesive protein of the extracellular matrix and it contains two apparently identical subunits with a range of binding sites for cell surface and extracellular ligands. It has been indicated that FN1 is involved in various aspects of cancer-related biological processes, such as cellular adhesion and migration. FN1 was identified to be overexpressed in hepatocellular, gastrointestinal, head and neck cancers ([@b25-ol-07-05-1537],[@b26-ol-07-05-1537]), which indicated its involvement in tumorigenesis. Furthermore, Waalkes demonstrated that advanced-stage renal cancer patients exhibited increased FN1 expression when compared with patients exhibiting organ-confined diseases ([@b27-ol-07-05-1537]). Thus, the present study provided a mechanistic insight into the role of COL6A3 in GC.

In conclusion, the present study indicated that COL6A3 was regularly overexpressed in GC cells. A list of potential partner genes of COL6A3 was generated, the majority of which are involved in cancer-related processes, and a functional network of COL6A3 was constructed, which provided promising results to enable future studies to identify the precise role of COL6A3.

![COL6A3 was overexpressed in gastric carcinoma tissue. (A) The expression pattern of COL6A3 in four GC datasets that were obtained using the Oncomine database; whiskers, 10th and 90th percentile; box boundaries, 75th and 25th percentile; line within the box, median. \*P\<0.001. (B) Relative COL6A3 expression of five GC cell lines (HGC-27, MGC80-3, SGC-7901, BGC-823 and AGS) compared with the mean value of a normal GC cell line (GES-1). COL6A3; collagen VI α3; GC, gastric cancer.](OL-07-05-1537-g00){#f1-ol-07-05-1537}

![Gene ontology analysis of collagen VI α3 co-expressed genes was conducted using the Database for Annotation, Visualization and Integrated Discovery functional annotation chart tool. ^\*^P\<0.01 for the pathway enrichment of COL6A3 co-expressed genes compared with *Homo sapiens* transcriptome background.](OL-07-05-1537-g01){#f2-ol-07-05-1537}

![Network construction of COL6A3 co-expressed genes. The biological interactions of COL6A3 co-expressed genes were analyzed and visualized using a gene expression pattern scanner. The category of each gene is distinguished by its shape for factors, such as kinases and transporters. The direction of the arrow demonstrates whether a gene is upstream or downstream of another gene. Dashed line, co-cited genes; solid line, genes with an expertly curated connection. Genes with no interactions are not shown.](OL-07-05-1537-g02){#f3-ol-07-05-1537}

###### 

Oncomine datasets obtained for use in the present study.

  Dataset (Ref no.)                         Samples                                                                                                         Data link
  ----------------------------------------- --------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------
  Chen Gastric ([@b11-ol-07-05-1537])       103 gastric adenocarcinomas and 29 normal gastric mucosa samples                                                <http://genome-www.stanford.edu/gastric_cancer2/index.shtml>
  Cho Gastric ([@b12-ol-07-05-1537])        65 gastric adenocarcinoma, 19 paired surrounding normal tissue and six gastrointestinal stromal tumor samples   <http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE13861>
  D'Errico Gastric ([@b13-ol-07-05-1537])   31 paired gastric carcinoma and adjacent normal gastric mucosa and seven unmatched gastric carcinoma samples    <http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE13911>
  Wang Gastric ([@b14-ol-07-05-1537])       12 paired gastric carcinoma and normal gastric mucosa samples and three normal gastric tissue samples           <http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE19826>

###### 

Collagen VI α3 co-expressed genes with the cut-off for selection defined as an appearance in two datasets.

  Gene        Gene name                                                                                          No. of appearances
  ----------- -------------------------------------------------------------------------------------------------- --------------------
  COL6A3      Collagen type VI α3                                                                                3
  COL1A2      Collagen type I α2                                                                                 3
  COL1A1      Collagen type I α1                                                                                 3
  COL12A1     Collagen type XII α1                                                                               3
  THY1        Thy-1 cell surface antigen                                                                         3
  THBS2       Thrombospondin 2                                                                                   3
  BGN         Biglycan                                                                                           3
  CTHRC1      Collagen triple helix repeat containing 1                                                          3
  SULF1       Sulfatase 1                                                                                        3
  FAP         Fibroblast activation protein-α                                                                    3
  SFRP4       Secreted frizzled-related protein 4                                                                3
  TIMP1       Tissue inhibitor of metallopeptidase 1                                                             3
  WNT2        Wingless-type mouse mammary tumor virus integration site family member 2                           3
  COL11A1     Collagen type XI α1                                                                                3
  BMP1        Bone morphogenetic protein 1                                                                       3
  SPOCK1      Sparc/osteonectin cwcv and kazal-like domains proteoglycan (testican) 1                            3
  SERPINH1    Serpin peptidase inhibitor clade H (heat shock protein 47) member 1 (collagen binding protein 1)   2
  CPXM1       Carboxypeptidase X (M14 family) member 1                                                           2
  INHBA       Inhibin β A                                                                                        2
  CDH11       Cadherin 11, type 2, OB-cadherin (osteoblast)                                                      2
  RAB31       Member of the RAS oncogene family                                                                  2
  ANTXR1      Anthrax toxin receptor 1                                                                           2
  NID2        Nidogen 2 (osteonidogen)                                                                           2
  PDGFRB      Platelet-derived growth factor receptor β polypeptide                                              2
  COL4A2      Collagen type IV α2                                                                                2
  COL4A1      Collagen type IV α1                                                                                2
  TGFBI       Transforming growth factor β-induced (68kDa)                                                       2
  PLAU        Plasminogen activator urokinase                                                                    2
  PRRX1       Paired related homeobox 1                                                                          2
  LOX         Lysyl oxidase                                                                                      2
  PLXDC2      Plexin domain containing 2                                                                         2
  LAMC1       Laminin γ1 (formerly LAMB2)                                                                        2
  OLFML2B     Olfactomedin-like 2B                                                                               2
  CLDN4       Claudin 4                                                                                          2
  FAM83D      Family with sequence similarity 83, member D                                                       2
  ITGB5       Integrin β5                                                                                        2
  TNC         Tenascin C                                                                                         2
  SNAI2       Snail family zinc finger 2                                                                         2
  FRMD6       FERM domain containing 6                                                                           2
  COL6A1      Collagen type VI α1                                                                                2
  NUAK1       NUAK family, SNF1-like kinase 1                                                                    2
  HSPG2       Heparan sulfate proteoglycan 2                                                                     2
  NOTCH3      Notch 3                                                                                            2
  CD276       Cluster of differentiation 276 molecule                                                            2
  WNT5A       Wingless-type mouse mammary tumor virus integration site family member 5A                          2
  ECM1        Extracellular matrix protein 1                                                                     2
  PDPN        Podoplanin                                                                                         2
  TNFAIP6     Tumor necrosis factor α-induced protein 6                                                          2
  ADAM12      A disintegrin and metallo-peptidase domain 12                                                      2
  GAS1        Growth arrest-specific 1                                                                           2
  THBS1       Thrombospondin 1                                                                                   2
  COL10A1     Collagen type X α1                                                                                 2
  FNDC1       Fibronectin type III domain containing 1                                                           2
  SPHK1       Sphingosine kinase 1                                                                               2
  MMP11       Matrix metallopeptidase 11 (stromelysin 3)                                                         2
  CST1        Cystatin SN                                                                                        2
  KRT80       Keratin 80                                                                                         2
  PMEPA1      Prostate transmembrane protein, androgen induced 1                                                 2
  SPP1        Secreted phosphoprotein 1                                                                          2
  TNFRSF11B   Tumor necrosis factor receptor superfamily, member 11b                                             2
  IGF2BP3     Insulin-like growth factor 2 mRNA binding protein 3                                                2
  MFAP2       Microfibrillar-associated protein 2                                                                2
  EHD2        EH-domain containing 2                                                                             2

###### 

GO and pathway enrichment analysis of COL6A3 co-expressed genes.

  Category        Term                                                       Function                   Count          P-value        Fold enrichment   FDR
  --------------- ---------------------------------------------------------- -------------------------- -------------- -------------- ----------------- --------------
  GOTERM \_BP_3   GO:0030198                                                 ECM organization           11             5.88×10^−12^   26.86738026       8.02×10^−9^
  GO:0048731      System development                                         29                         2.30×10^−9^    3.161608227    3.13×10^−6^       
  GO:0048513      Organ development                                          24                         2.54×10^−8^    3.507740409    3.47×10^−5^       
  GO:0009653      Anatomical structure morphogenesis                         19                         2.42×10^−7^    4.032045523    3.30×10^−4^       
  GO:0009888      Tissue development                                         14                         9.88×10^−7^    5.347765641    1.35×10^−3^       
  GO:0022603      Regulation of anatomical structure morphogenesis           7                          1.89×10^−4^    8.119324546    2.57×10^−1^       
  GO:0030154      Cell differentiation                                       17                         3.01×10^−4^    2.637947926    4.10×10^−1^       
  GO:0051093      Negative regulation of developmental process               7                          4.64×10^−4^    6.865374809    6.31×10^−1^       
  GO:0031589      Cell-substrate adhesion                                    5                          5.47×10^−4^    12.96014632    7.43×10^−1^       
  GO:0051239      Regulation of multicellular organismal process             12                         7.52×^−4^      3.253176537    1.02              
  GO:0048519      Negative regulation of biological process                  17                         9.44×10^−4^    2.383179224    1.28              
  GO:0050793      Regulation of developmental process                        10                         9.95×10^−4^    3.768825934    1.35              
  GO:0060348      Bone development                                           5                          1.28×10^−3^    10.32597024    1.73              
  GO:0009887      Organ morphogenesis                                        9                          1.33×10^−3^    4.053492573    1.80              
  GO:0006928      Cell motion                                                8                          2.20×10^−3^    4.278212512    2.96              
  GO:0042127      Regulation of cell proliferation                           10                         2.90×10^−3^    3.227685742    3.88              
  GO:0032101      Regulation of response to external stimulus                5                          3.27×10^−3^    7.988014715    4.36              
  GO:0002683      Negative regulation of immune system process               4                          4.02×10^−3^    12.24187315    5.34              
  GO:0009611      Response to wounding                                       8                          4.05×10^−3^    3.834247063    5.39              
  GO:0030334      Regulation of cell migration                               5                          4.06×10^−3^    7.515351122    5.40              
  GO:0016477      Cell migration                                             6                          4.13×10^−3^    5.522149303    5.49              
  GO:0016337      Cell-cell adhesion                                         6                          4.13×10^−3^    5.522149303    5.49              
  GO:0050865      Regulation of cell activation                              5                          4.60×10^−3^    7.257681941    6.08              
  GO:0008284      Positive regulation of cell proliferation                  7                          5.02×10^−3^    4.295005013    6.64              
  GO:0009790      Embryonic development                                      8                          5.90×10^−3^    3.577730534    7.75              
  GO:0007566      Embryo implantation                                        3                          5.94×10^−3^    25.40188679    7.80              
  GO:0044259      Multicellular organismal macromolecule metabolic process   3                          6.33×10^−3^    24.58247109    8.30              
  GO:0040012      Regulation of locomotion                                   5                          6.37×10^−3^    6.615074686    8.34              
  GO:0051272      Positive regulation of cell motion                         4                          6.39×10^−3^    10.36811706    8.36              
  GO:0040017      Positive regulation of locomotion                          4                          6.39×10^−3^    10.36811706    8.36              
  GO:0048870      Cell motility                                              6                          6.46×10^−3^    4.964538135    8.46              
  GO:0051270      Regulation of cell motion                                  5                          6.48×10^−3^    6.580799687    8.49              
  GO:0048523      Negative regulation of cellular process                    14                         8.98×10^−3^    2.142327802    11.57             
  GO:0050867      Positive regulation of cell activation                     4                          9.00×10^−3^    9.153833078    11.59             
  GO:0009792      Embryonic development ending in birth or egg hatching      6                          9.13×10^−3^    4.563213196    11.76             
  GO:0032844      Regulation of homeostatic process                          4                          9.67×10^−3^    8.912942734    12.41             
  GOTERM_CC_3     GO:0031012                                                 ECM                        26             2.51×10^−26^   19.52139523       2.54×10^−23^
  GO:0005578      Proteinaceous ECM                                          25                         1.40×10^−25^   20.23702331    1.41×10^−22^      
  GO:0044420      ECM part                                                   15                         8.00×10^−18^   33.20947414    8.10×10^−15^      
  GO:0005581      Collagen                                                   10                         5.53×10^−15^   74.00968523    5.62×10^−12^      
  GO:0005604      Basement membrane                                          6                          1.13×10^−5^    19.92568449    1.14×10^−2^       
  GO:0005615      Extracellular space                                        12                         4.49×10^−5^    4.537820116    4.55×10^−2^       
  GO:0005886      Plasma membrane                                            25                         3.82×10^−3^    1.71454791     3.80              
  GO:0031252      Cell leading edge                                          3                          9.65×10^−2^    5.631171702    64.22             
  GOTERM_MF_3     GO:0019838                                                 Growth factor binding      6              3.98×10^−5^    15.21982507       3.80×10^−2^
  GO:0005518      Collagen binding                                           4                          3.06×10^−4^    29.59410431    2.92×10^−2^       
  GO:0005102      Receptor binding                                           11                         1.21×10^−3^    3.306790436    1.15              
  KEGG_PATHWAY    hsa04512                                                   ECM-receptor interaction   14             1.41×10^−16^   28.25             9.99×10^−14^
  hsa04510        Focal adhesion                                             14                         1.52×10^−11^   11.80597015    1.35×10^−08^      

GO, gene ontolgy; COL6A3, collagen VI α3; FDR, false discovery rate; BP; biological process; CC, cellular constituent; ECM, extracellular matrix; MF, molecular function; KEGG, Kyoto encyclopedia of genes and genomes. P\<0.01 indicated a statistically significant difference.
